Powers Principal William von Oehsen spoke about changes to the 340B program and how these modifications could affect covered entities at the 12th Annual “Big 4” Pharmaceutical Pricing Boot Camp in New York City last week.

The “Big 4” pharmaceutical pricing boot camp is a training course designed to provide attendees with a complete understanding of core drug pricing competencies. Sessions included topics like current issues in pricing and contracting, audit risks and penalties and Federal Supply Schedule contracts.

Bill’s session, “Managing the Implementation and Operational Challenges Resulting from Significant Changes to the 340B Program,” covered the purpose and function of the 340B drug discount program, how covered entities can become eligible for the 340B program and the impact of the CMP final rule.

Additionally, Bill discussed penny pricing, distribution systems, calculation of the 340B price, best practices for monitoring HRSA data, and the treatment of 340B sales in other federal drug pricing calculations.

Drug Pricing and 340B Attorney William von Oehsen

Bill von Oehsen has more than 25 years of experience on pharmaceutical pricing and reimbursement matters, including the 340B drug discount program, the Medicaid drug rebate program, Medicare Part D, Robinson-Patman and state Medicaid and pharmacy laws. He played a key role in helping to enact the 340B program in 1992, as well as to expand the law in 2010 under the Affordable Care Act.

Additionally, Bill has helped to establish and serves as outside counsel to 340B Health, an advocacy organization of more than 1,300 public and private nonprofit hospitals participating in the 340B program. He also helped organize the 340B Coalition, which now represents a dozen national organizations whose members comprise virtually all of the safety net providers participating in the 340B program.

For more information regarding the 340B program or drug pricing, contact Bill von Oehsen at 202-872-6765 or William.vonOehsen@powerslaw.com.

Leave a Reply